David Farrugia

1.5k total citations
29 papers, 429 citations indexed

About

David Farrugia is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, David Farrugia has authored 29 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 6 papers in Epidemiology. Recurrent topics in David Farrugia's work include Colorectal Cancer Treatments and Studies (7 papers), Gastric Cancer Management and Outcomes (6 papers) and Lung Cancer Treatments and Mutations (5 papers). David Farrugia is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Gastric Cancer Management and Outcomes (6 papers) and Lung Cancer Treatments and Mutations (5 papers). David Farrugia collaborates with scholars based in United Kingdom, Germany and Malta. David Farrugia's co-authors include Ann L. Jackman, Susannah Eykyn, Emer Smyth, G. Wynne Aherne, T C Stephens, Rosemary Kimbell, David Cunningham, William Gibson, Kenneth R. Harrap and M. Azab and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Infectious Diseases.

In The Last Decade

David Farrugia

28 papers receiving 413 citations

Peers

Countries citing papers authored by David Farrugia

Since Specialization

Citations

This map shows the geographic impact of David Farrugia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Farrugia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Farrugia more than expected).

Fields of papers citing papers by David Farrugia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Farrugia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Farrugia. The network helps show where David Farrugia may publish in the future.

Co-authorship network of co-authors of David Farrugia

This figure shows the co-authorship network connecting the top 25 collaborators of David Farrugia. A scholar is included among the top collaborators of David Farrugia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Farrugia. David Farrugia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Management and Outcomes of Immune-Related Adverse Events During Treatment with Immune Checkpoint Inhibitor Therapies in Melanoma and Renal Cell Carcinoma: A UK Real-World Evidence Study 2025 ·Oncology and Therapy ·Anna Olsson‐Brown, Ankit Jain, (unknown), David Farrugia, Judith Carser, John Houghton, (unknown), (unknown), (unknown)	1
2	Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series. 2023 ·Journal of Clinical Oncology ·Xiuning Le, Anna Eisert, Te‐Chun Hsia, Nirmal Vivek Raut, (unknown), Oscar S.H. Chan, Charlotte De Bondt, David Farrugia, Patrizia Froesch, María González‐Cao, Lizza Hendriks, Maximilian J. Hochmair, Julien Mazières, (unknown), Jens Samol, Anthonie J. van der Wekken, Tsung‐Ying Yang, (unknown), Soetkin Vlassak, Gee‐Chen Chang	0
3	A decision-making tool for first-line treatment in advanced non–small-cell lung cancer based on plasma proteome biomarkers. 2023 ·Journal of Clinical Oncology ·(unknown), Petros Christopoulos, Igor Puzanov, Jair Bar, Alona Zer, Mor Moskovitz, Niels Reinmuth, (unknown), (unknown), Abed Agbarya, David Farrugia, Gillian Price, (unknown), (unknown), Kimberly McGregor, Yanyan Lou, Raya Leibowitz‐Amit, Adam P. Dicker, David P. Carbone, David R. Gandara	1
4	1116P United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review 2022 ·Annals of Oncology ·(unknown), (unknown), Colin R. Lindsay, (unknown), M. Button, Nicola Steele, (unknown), (unknown), (unknown), David Farrugia, (unknown), (unknown), (unknown), Shobhit Baijal, (unknown), T. Geldart, (unknown), (unknown), Alastair Greystoke, Tom Newsom‐Davis	2
5	A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial 2022 ·Clinical Genitourinary Cancer ·Anjali Zarkar, Sarah Pirrie, Clive Stubbs, (unknown), David Farrugia, Kathryn Fife, (unknown), Naveen Vasudev, Emilio Porfiri	2
6	Complete remission of advanced, locally invasive basal cell carcinoma with vismodegib 2020 ·International Journal of Oral and Maxillofacial Surgery ·Paul Glen, David Farrugia, (unknown)	4
7	UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE study 2016 ·Annals of Oncology ·John Ramage, (unknown), Olusola Olusesan Faluyi, Andrea Frilling, Tim Meyer, Gaurav Kapur, Judith Cave, Jonathan Wadsley, S. Cummins, David Farrugia, Naureen Starling, Lucy Wall, (unknown), Juan W. Valle	1
8	Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia? 2014 ·European Respiratory Journal ·Caroline Gouder, (unknown), (unknown), (unknown), David Farrugia, Michael Borg, (unknown)	2
9	Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours 2011 ·British Journal of Cancer ·Louise Medley, Alain Morel, David Farrugia, Nicholas S. Reed, Nicholas K. Hayward, J M Davies, Oksana Kirichek, Rajesh V. Thakker, D C Talbot	25
10	Use of electronic pagers to recall patients undergoing outpatient-based chemotherapy 2006 ·European Journal of Oncology Nursing ·David Farrugia, (unknown), (unknown), (unknown)	9
11	Long-Term Outcomes in Patients with Prostate Cancer Managed with Intermittent Androgen Suppression 2004 ·Urologia Internationalis ·Tim Lane, Wendy Ansell, David Farrugia, Peter Wilson, Geraint P. Williams, Frank Chinegwundoh, T. Philp, John Hines, R.T.D. Oliver	33
12	Reversible Life-threatening Encephalopathy in the Absence of Hepatic Failure Following Conventional Doses of Docetaxel 2003 ·Clinical Oncology ·Sam Guglani, David Farrugia, (unknown), Malvinder S. Parmar, John R. Owen	1
13	Clinical testing of Ukrain – Authors' reply 2001 ·The Lancet Oncology ·David Farrugia, M L Slevin	1
14	Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone‐releasing hormone analogues and orchidectomy 2000 ·British Journal of Urology ·David Farrugia, Wendy Ansell, (unknown), T. Philp, Frank Chinegwundoh, R.T.D. Oliver	32
15	Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies. 2000 ·PubMed ·David Farrugia, G. Wynne Aherne, Lisa Brunton, Stephen Clarke, A.L. Jackman	18
16	Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex®) in advanced colorectal cancer 1998 ·European Journal of Cancer ·David Farrugia, A. R. Norman, David Cunningham	5
17	Unknown primary carcinoma: Randomised studies are needed to identify optimal treatments and their benefits 1996 ·European Journal of Cancer ·David Farrugia, A. Norman, M. Nicolson, Martin Gore, (unknown), Andrew Webb, David Cunningham	8
18	Primary osteosarcoma of the breast 1995 ·European Journal of Surgical Oncology ·David Farrugia, (unknown), Mike Parker	6
19	ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer 1995 ·European Journal of Cancer ·Ann L. Jackman, David Farrugia, William Gibson, Rosemary Kimbell, Kenneth R. Harrap, T C Stephens, M. Azab, (unknown)	89
20	Campylobacter fetus Endocarditis: Two Case Reports and Review 1994 ·Clinical Infectious Diseases ·David Farrugia, Susannah Eykyn, Emer Smyth	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact